BioTuesdays

Category - Markets

Markets

Dawson James ups CollPlant PT to $15 from $9

Dawson James Securities raised its price target for CollPlant Biotechnologies (NASDAQ:CLGN) to $15 from $9, reflecting an “increase in valuation, which translates into less dilution in terms of our assumptions around...

January 27, 2020
Itamar Medical
Markets

AGP ups Itamar Medical PT to $19.50 from $15.50

Alliance Global Partners raised its price target for Itamar Medical (NASDAQ:ITMR) to $19.50 from $15.50, reflecting preliminary fourth quarter revenue results, 2020 guidance and a recent meeting with the company’s...

January 22, 2020
ArTara Therapeutics
Markets

Ladenburg starts ArTara Therapeutics at buy; PT $45

Ladenburg Thalmann initiated coverage of ArTara Therapeutics (NASDAQ:TARA) with a “buy” rating and $45 price target. The stock closed at $28.34 on Jan. 21. ArTara has two late-stage clinical assets in development for...

January 22, 2020
Protech Home Medical
Markets

Echelon starts Protech Home Medical at buy; PT $2.50

Echelon Wealth Partners launched overage of Protech Home Medical (TSXV:PTQ) with a “buy” rating and price target of $2.50. The stock closed at 91 cents on Jan. 22. “We believe the firm is well positioned within [the...

January 22, 2020
Capricor Therapeutics
Markets

HCW lowers Capricor Therapeutics PT to $9

H.C. Wainwright lowered its price target for Capricor Therapeutics (NASDAQ:CAPR) to $9.50 based on a higher fully diluted share count but maintained its “buy” rating. The stock closed at $1.83 on Jan. 17. Analyst Joseph...

January 21, 2020
Accuray
Markets

BTIG ups Accuray to buy; PT $9.50

BTIG upgraded Accuray (NASDAQ:ARAY) to “buy” from “neutral,” with a price target of $9.50. The stock closed at $3.28 on Jan. 17. Last week, Accuray announced a compound annual growth rate revenue outlook of 8% to 12%...

January 21, 2020
Mersana Therapeutics
Markets

HCW ups Mersana Therapeutics PT to $12 from $7

H.C. Wainwright raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $12 from $7, saying the expected data flow, and available activity and safety profile bode well for the company’s XMT-1536 drug candidate...

January 21, 2020
Acasti Pharma
Markets

Mackie puts Acasti Pharma under review; removes PT

Mackie Research Capital put Acasti Pharma (NASDAQ, TSXV:ACST) “under review” and removed its price target after the company’s pivotal TRILOGY-1 trial missed its primary endpoint because of an unexplained high placebo...

January 13, 2020

Subscribe

Sign up to our weekly BioTuesdays newsletter.